You are here: / / SuperGen Presents Preclinical Data at EORTC On MP-529, a Selective Kinase...

SuperGen Presents Preclinical Data at EORTC On MP-529, a Selective Kinase Inhibitor and CLIMB™ Process in Drug Discovery and Design

/in ,

SuperGen Presents Preclinical Data at EORTC On MP-529, a Selective Kinase Inhibitor and CLIMB™ Process in Drug Discovery and Design

SuperGen Reports 2006 Third Quarter Financial ResultsSuperGen Presents Preclinical Data on Selected Lead Kinase Compounds and DNA...